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Abstract Introduction: Antimicrobial resistance (AMR) is a complex problem that affects 
all of society and is driven by many interconnected factors.  It is important to 
monitor AMR trends in veterinary medicine to accurately pursue appropriate 
antibiotic treatment of ill animals.  Antibiogram development is also an important 
tool in guiding the veterinary practitioner in treating empirically or while a culture 
and susceptibility is being performed. 
 
 Methods: This study compared bacterial susceptibility in voluntary samples 
submitted to the University of Kentucky Veterinary Diagnostic Laboratory and the 
Murray State University Breathitt Veterinary Center between 2012 and 2017.  
Equality of proportions was used to compare 40 isolate/antibiotic pairs in 2012 
and 2017. 
 
 Results: There was a significant increase in E. coli’s susceptibility to ampicillin 
(p-value = 0.0243, CI 0.0138, 0.1928), gentamicin (p-value = 0.002, CI 0.0387, 
0.1649), neomycin (p-value = 0.0003, CI 0.0731, 0.2334, and oxytetracycline (p-
value = 0.0444, CI 0.0027, 0.2032).  There was a significant decrease in 
Enterococcus’s susceptibility to trimethoprim/sulphamethoxazole (p-value = 
<0.001, CI 0.5243, 1).  There was a significant increase in Histophilus somni’s 
susceptibility to enrofloxacin (p-value = 0.0028, CI 0.1081, 0.474).  There was a 
significant increase in Mannheimia haemolytica’s susceptibility to enrofloxacin (p-
value = 0.0013, CI 0.0752, 0.3024), florfenicol (p-value = 0.0041, CI 0.0533, 
0.2759), spectinomycin (p-value = <0.001, CI 0.1748, 0.3895), and tulathromycin 
(p-value = 0.0023, CI 0.0656, 0.2953).   
 
 Conclusion/Discussion:  It will be important to continue to monitor use of 
antibiotics that are considered medically important in human medicine.  The 
Veterinary Feed Directive is a step in the right direction to promote good 
antibiotic stewardship.  Antibiotics used in metaphylaxsis should be reviewed for 
susceptibility to ensure the proper antibiotics are used in a given population.  
Antibiograms, whether a chart or a map, can be beneficial for veterinarians in 
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 Antimicrobial resistance (AMR) is a complex problem that affects all of society and is 
driven by many interconnected factors.[1]  It has been estimated that AMR is currently 
responsible for killing 700,000 people per year globally and has been projected to kill as many 
as 10 million people per year by 2050.[2]  Each year in the United States, at least 2 million 
people become infected with bacteria that are resistant to antibiotics and at least 23,000 
people die each year as a direct result of these infections.[3]  These antimicrobial resistant 
infections costs the United States an estimated $20 billion in direct healthcare costs and $35 
billion in lost productivity.[3]  
Antimicrobial resistant-microbes are found in people, animals, food, and the 
environment (in water, soil and air). They can spread between people and animals, including 
from food of animal origin, and from person to person.[1]  The One Health Initiative recognizes 
that human, animal and environmental health are closely linked, and that collaboration to 
achieve solutions to problems that span these realms, such as antimicrobial resistance, is 
imperative.[4]  The National Action Plan for Combating Antibiotic-Resistant Bacteria also 
acknowledged that there must be a common effort among public health, healthcare, and 
veterinary partners to address the urgent and serious drug resistant threats that affect the 
people of the United States and around the world.[5]  As such, both the human medicine and 
animal medicine entities have taken measures to address potentiating the speed of 
antimicrobials resistance.   
In order to slow the development of AMR, judicious use of antibiotics is key.  However, 







susceptibility tests are being performed.  To focus this empiric use of antibiotics, The World 
Health Organization has compiled information and made it available to all countries on how to 
implement some changes to target antibiotic use.  One of their recommendations is the 
development of cumulative antibiograms.  An antibiogram represents a report which 
summarizes the susceptibility of commonly isolated microorganisms to usual antibiotics in a 
defined period of time.[6]  These antibiograms guide clinicians in their antibiotic choice while 
waiting for culture and susceptibility results by using the most appropriate antibiotic to the 
suspected offending  bacteria. 
 
Veterinary Feed Directive 
In animal production, antimicrobials are used for growth promotion, disease prevention, 
and disease treatment.  The use of antimicrobials for growth promotion has been under heavy 
criticism as they are subtherapeutic with potential to create AMR.[7]  In response to this, the 
National Action Plan for Combating Antibiotic-Resistant Bacteria outlined that the Food and 
Drug Administration (FDA) would eliminate the use of medically important antibiotics for growth 
promotion in food-producing animals and bring under veterinary oversight other in-feed and in-
water uses of antibiotics that are medically important for treatment, control, and prevention of 
disease.[5]  With this guidance, the FDA developed the Veterinary Feed Directive which 
became effective 1 January 2017.  A full list of medically important antibiotics in human health 
can be found in Appendix A. 
To promote the judicious use of and reduce the misuse or overuse of antimicrobials in 
food animal production, the Veterinary Feed Directive (VFD) eliminated the availability of over-







health.[8, 9]  Drug  sponsors, working with the FDA, voluntarily removed production claims 
from their labels that stated the antibiotic can be for growth promotion or feed efficiency and 
the use of the antibiotic for those purposes are no longer legal.[8, 9]  VFD feeds, feeds  
 containing approved VFD drugs, can only be prescribed by 
a licensed veterinarian and only when a valid veterinarian-
client-patient relationship exists.  The current list of drugs 
that require a VFD from a licensed veterinarian can be found 
in Figure 1.[10]  It will be important to follow antimicrobial 
resistance trends in both human and animal samples to 
determine if the VFD is effective. 
 
        Figure 1. Antimicrobials Requiring a VFD  
National Antimicrobial Resistance Monitoring System 
Established in 1996, the National Antimicrobial Resistance Monitoring System for 
Enteric Bacteria (NARMS) is a collaboration between the Centers for Disease Control (CDC) 
and Prevention, the Food and Drug Administration (FDA), and the United States Department of 
Agriculture (USDA).[11]  NARMS is a national public health surveillance system that tracks 
changes in the antimicrobial susceptibility of certain enteric (intestinal) bacteria found in ill 
people (CDC), retail meats (FDA), and food animals (USDA) in the United States.[11]  The four 
bacteria monitored by the USDA are Campylobacter, E. coli, Enterococcus, and 
Salmonella.[12]  These four bacterial species are capable of sharing their antimicrobial 
resistant genes and have zoonotic potential.  Of the 15 health departments and 4 universities 


























potential to be a valid site to include in the NARMS surveillance programs as Kentucky is the 
14th largest beef cattle producer in the United States and the largest beef cattle producer east 
of the Mississippi River and has a total cattle population of approximately 2.15 million 
cattle.[14, 15]  
 
Bovine Respiratory Disease and Metaphylaxsis 
Bovine respiratory disease (BRD) complex, also known as shipping fever and bovine 
bronchopneumonia/pneumonia, is the most common cause of morbidity and mortality and the 
most costly disease of beef cattle, costing the cattle industry approximately $1 billion in death 
losses.[16, 17]  BRD is associated with stressors such as shipping and herd intermingling, with 
or without viral infection, interacting and suppressing the host’s immune system, allowing for 
proliferations of commensal bacteria.[18]  The important bacterial agents associated with this 
disease process are Mannheimia haemolytica (formerly Pasteurella haemolytica), Pasteurella 
multocida, and Histophilus somni (formerly Haemophilus somnus).[18, 19]  Klima et al looked 
at biological samples from 68 cattle in North America diagnosed with BRD on necropsy and 
found that Mannheimia haemolytica was present in 91% of those cattle, 57% had Histophilus 









In a survey conducted in 2011 by the USDA’s National Animal Health Monitoring 
System (NAHMS) revealed that 16.2% of feedlot cattle are affected with bovine respiratory 
disease, that 87.5% of those cattle were treated, and that 100% of those treated cattle were 
given injectable antibiotics.[21]  Morbidity associated with BRD has also been reported as high 
as 35-50% with mortality reaching 5-10%.[18]  BRD has been a growing concern as cattle 
entering the feedlots during 1999 had a significantly increased risk (relative risk, 1.46) of dying 
of respiratory tract disorders, compared with cattle that entered during 1994, with respiratory 
tract disorders accounting for 57.1% of all deaths.[22]  There are many factors that can 
potentiate BRD in a herd.  See Figure 3 for pre-weaning and post-weaning factors that 
influence BRD and the resulting outcomes of the disease, which include feedlot performance, 
feedlot health, and carcass quality.[23]  Cattle that are infected with bovine viral diarrhea virus 
(BVDV) intrauterine become persistently infected (PI).  PI cattle are not only over-represented 
among chronically ill and dying cattle in feedlots, but they also shed large quantities of BVDV, 
increasing the risk of the other cattle in their lots becoming infected and being at an increased 
risk of developing BRD.[24]  Loneragan et al found that exposure to PI cattle increased risk of 
treatment for BRD.[25]  These conditions create a scenario where a large amounts of 












There has been growing concern of antimicrobial resistance in veterinary medicine and 
has been a topic of discussion at professional veterinary meetings.  Bovine respiratory disease 
is of concern because of its prevalence and due to the associated overlapping use of long-
acting antibiotics.  This has implications in both veterinary medicine and human medicine in 
regard to appropriate antibiotic use in attempts to minimize antimicrobial resistance.  It also 
has implications in a secure food chain.  Due to the high prevalence of BRD among feedlot 
cattle, established metaphylaxsis protocols have been utilized to treat all calves upon arrival to 







population.[16]  Whether metaphylaxsis or treatment is the course of action for a given feedlot, 
they both present scenarios where large amounts of antibiotics are used. 
Five antibiotics labeled for use as metaphylaxsis are: Micotil® (tilmicosin); Nuflor® 
(florfenicol), 300 PRO LA® (oxytetracycline 300 mg/ml), Excede® (ceftiofur 200mg/ml), and 
Draxxin® (tulathromycin).[26-29]  This list was not meant to be exhaustive, but to provide at 
least one brand drug from each antibiotic class that is used for metaphylaxsis.  Each of these 
antibiotics come with the additional wording for the applicable pathogens that this medication 
can be used “for the control of respiratory disease in cattle at high risk of developing BRD”. 
 
Study Aims 
 The aim of this study is to review the trends of antimicrobial resistance of select 
bacterial culture and susceptibility tests performed at the University of Kentucky’s Veterinary 
Diagnostic Laboratory and the Murray State University Breathitt Veterinary Center to determine 
if there is a significant change in susceptibility between 2012 and 2017.  This study will display 




Participants and Materials 
Bacterial isolates of interest and their susceptibility results were collected from the 
University of Kentucky Veterinary Diagnostic Laboratory (UKVDL) and Murray State University 
Breathitt Veterinary Center (MSU-BVC) culture and susceptibility (C&S) submissions, for the 







cattle producers and veterinarians, and from veterinary pathologists working with these 
laboratories.  Only bovine samples listed as originating within the state of Kentucky were 
included in this study.  The data from UKVDL was retrieved from their online Animal Disease & 
Diagnosis Mapping Initiative.[30]  The data from MSU-BVC was retrieved via electronic 
request.   Both laboratories used minimal inhibitory concentrations (MICs) for all isolates to 
determine susceptibility.  Both the UKVDL and the MSU-BVD are fully accredited by the 
American Association of Veterinary Laboratory Diagnosticians.   
The bacterial isolates of interest included the top three causative bacterial agents of 
Bovine Respiratory Disease:  Mannheimia haemolytica, Histophilus somni, and Pasteurella 
multocida.  They also included the four enteric bacteria of interest identified by the National 
Antimicrobial Resistance Monitoring System: Campylobacter, E. coli, Enterococcus, and 
Salmonella.[12]  There was only one isolate of Campylobacter reported during the timeframe 
of this study and will be excluded from this study.  Only C&S with the results of “Intermediate”, 
“Resistant”, or “Susceptible” were used in this study.  C&S with a result listed as “No 
Interpretation” were excluded.  Only samples originating from within Kentucky were included in 
this study. 
The antimicrobials were selected based on the following criteria: that they were tested in 
both reporting laboratory’s C&Ss, the antimicrobial was either labeled for use in animals 
against one or more of the bacteria of interest and/or literature supported valid use of the 
medication in human medicine.  See Appendix B for a list of the selected antimicrobials and 
their categorization as either critically important, highly important, or important as compared to 
medically important in human medicine.  It was noted that Zoetis had distributed a 







could no longer be found in their catalog.  Spectinomycin was included in this study for 
completeness as it can still be found in feed supply stores, but is labelled for use in pigs.  
Based on these criteria, the following bacterium/antimicrobial combinations were tested: 
 
 E. coli (all subspecies cultured): Ampicillin, Chlortetracycline, Enrofloxacin, 
Gentamicin, Neomycin, Oxytetracycline 
 
 Enterococcus (all subspecies cultured): Ampicillin, Gentamicin, Penicillin, 
Trimethoprim/Sulphamethoxazole 
 
 Histophilus somni: Ampicillin, Ceftiofur, Enrofloxacin, Florfenicol, 
Oxytetracycline, Spectinomycin, Tilmicosin, Tulathromycin 
 
 Mannheimia haemolytica: Ceftiofur, Danofloxacin, Enrofloxacin, 
Florfenicol, Spectinomycin, Tilmicosin, Tulathromycin 
 
 Pasteurella multocida: Ampicillin, Ceftiofur, Chlortetracycline, 
Danofloxacin, Enrofloxacin, Florfenicol, Oxytetracycline, Penicillin, 
Spectinomycin, Sulfadimethoxine, Tilmicosin, Tulathromycin 
 
 Salmonella (all subspecies cultured):  Enrofloxacin, Gentamicin, 
Sulfadimethoxine 
 
This selection of bacterium/antimicrobial pairs created a total of 21,842 isolates/antibiotic 
















2012  2013  2014  2015  2016  2017  All Years  Total 
               
E. coli*  Ampicillin  227  257  269  292  301  186  1532   
  Chlortetracycline  212  244  261  282  291  154  1444   
  Enrofloxacin  213  246  265  283  287  139  1433   
  Gentamicin  218  246  265  283  292  179  1482   
  Neomycin  211  244  261  281  291  154  1442   
  Oxytetracycline  212  243  261  283  291  154  1444  8777 
                   
Enterococcus*   Ampicillin  25  35  22  44  29  11  166   
  Gentamicin  16  24  17  38  24  7  123   
  Penicillin  25  35  21  44  29  11  165   
  Trimethoprim/ 
Sulphamethoxazole 
16  24  17  38  24  5  124  578 
                   
Histophilus somni    Ampicillin  45  38  40  52  36  40  251   
  Ceftiofur  45  38  40  52  35  38  248   
  Enrofloxacin  45  38  40  52  35  38  248   
  Florfenicol  45  38  40  52  36  44  255   
  Oxytetracycline  38  38  40  52  36  40  244   
  Spectinomycin  45  38  39  52  36  44  254   
  Tilmicosin  45  38  39  52  36  40  250   
  Tulathromycin  45  38  39  52  35  38  247  1997 
                   
Mannheimia haemolytica  Ceftiofur  148  143  108  139  125  127  790   
  Danofloxacin  44  55  40  69  58  64  330   
  Enrofloxacin  147  143  109  140  125  127  791   
  Florfenicol  147  143  108  139  127  133  797   
  Spectinomycin  147  143  108  138  127  133  796   
  Tilmicosin  147  143  108  139  127  133  797   
  Tulathromycin  147  143  107  138  125  127  787  5088 
                   
Pasteurella multocida  Ampicillin  70  67  65  71  60  91  424   
  Ceftiofur  68  67  65  70  61  90  421   
 Chlortetracycline  59  67  65  71  61  70  393   
 Danofloxacin  58  48  58  66  56  81  367   
 Enrofloxacin  70  67  65  71  61  90  424   
 Florfenicol  70  67  65  72  61  92  427   
 Oxytetracycline  59  67  65  71  61  70  393   
 Penicillin  68  67  65  72  60  90  422   
 Spectinomycin  70  67  65  70  61  92  425   
 Sulfadimethoxine  59  67  65  72  61  70  394   
 Tilmicosin  59  67  65  71  61  70  393   
 Tulathromycin  67  67  65  70  61  90  420  4903 
                  
Salmonella* Enrofloxacin  37  38  25  25  29  21  165   
 Gentamicin  38  28  25  25  29  25  170   












Design and Procedure 
Percent Susceptible 
The percentage of isolates susceptible to any of the antimicrobials was defined as the 
number of isolates susceptible to each antimicrobial divided by the total number of isolates 
with a valid result (Intermediate, Resistant, and Susceptible) tested for each antimicrobial.  
Equality of proportion will be utilized to determine if there is a significant change in 
susceptibility from 2012 to 2017. 
 
Antibiogram Development 
 A minimum of 30 isolates of a given bacterium is recommended when developing an 
antibiogram.  Those isolates are recommended to come from the most recent year (2017, in 
this case), but if the number is too low, the previous year’s isolates can be included.[6]  The 
low numbers of isolates from multiple counties, coinciding with a low number of cattle in that 
county, led to antibiograms being developed for Kentucky’s 15 Area Development Districts 
(ADDs).  Despite consolidating counties into their respective ADDs, numbers for several 
bacterium/antimicrobial pairings were still below 30 and all years (2012-2017) of isolates were 
included in some instances to get as many ADDs over 30 isolates as possible.  When possible, 
only the results from 2017 were used in the development of antibiograms.  When necessary, 
isolates from previous years were added until there was a minimum or 30 isolates or until all 
years in the study (2012-2017) had been included.  If an antibiogram included data from a 
previous year(s), results from the entire year were included. 
 In this study, as Mannheimia haemolytica is the most common isolate found in cattle 







evidence that indicates Mannheimia haemolytica is becoming increasingly resistant to current 
antibiotics, so this study’s antibiograms will focus on this bacterium.[31]  Five antibiotics 
labeled for use as metaphylaxsis: Micotil® (tilmicosin); Nuflor® (florfenicol), 300 PRO LA® 
(oxytetracycline 300 mg/ml), Excede® (ceftiofur 200mg/ml), and Draxxin® (tulathromycin).[26-
29]  This list was not meant to be exhaustive, but to provide at least one drug from each 
antibiotic that is used for metaphylaxsis.  Each of these antibiotics come with the additional 
wording for the applicable pathogens that this medication can be used “for the control of 
respiratory disease in cattle at high risk of developing BRD”. 
 
Statistical Analysis 
Data were maintained in a spreadsheet (Microsoft Excel).  Maps were created in 
ArcMap (ESRI 2001. ArcGIS Desktop: Release 10.  Redlands, CA: Environmental Systems 
Research Institute).  Descriptive statistics were performed using commercially available 
software (Microsoft Excel 2010; Microsoft Corporation, Redmond, Washington, USA), SAS 9.4 
(SAS Institute Inc., Cary, NC, USA), and Vassarstats.net (Richard Lowry, PhD, Professor of 
Psychology Emeritus, Vassar College, Poughkeepsie, NY, USA).  Equality of proportions 
(ChiSq) was used to compare susceptibility rates between years.  All analyses were conducted 
with significance level of 5% (p-value < 0.05).[32] 
 
Results 
Susceptibility Trends, 2012-2017 
 Table 2 displays the proportion of equality results.  Following Table 2, each bacteria’s 
























             
E. coli*  Ampicillin  227  60.35  186  70.97  0.0243  0.1062  0.0138, 0.1928 
  Chlortetracycline  212  40.57  154  43.51  0.5734  0.0294  ‐0.0719, 0.1309 
  Enrofloxacin  213  80.28  139  87.77  0.0660  0.0749  ‐0.0057, 0.1485 
  Gentamicin  218  83.03  179  93.3  0.002  0.1027  0.0387, 0.1649 
  Neomycin  211  72.04  154  87.66  0.0003  0.1562  0.0731, 0.2334 
  Oxytetracycline  212  34.43  154  44.81  0.0444  0.1037  0.0027, 0.2032 
                 
Enterococcus*   Ampicillin  25  100  11  100  N/A  0  ‐0.1332, 0.2588 
  Gentamicin  16  43.75  7  42.86  0.6868  0.0089  ‐0.3727, 0.3643 








Ampicillin  45  100  40  100  N/A  0  ‐0.0787, 0.0876 
  Ceftiofur  45  100  38  100  N/A  0  ‐0.0787, 0.0918 
  Enrofloxacin  45  53.33  38  84.21  0.0028  0.3088  0.1081, 0.474 
  Florfenicol  45  82.22  44  95.45  0.0987  0.1323  ‐0.0034, 0.2718 
  Oxytetracycline  38  28.95  40  47.5  0.0923  0.1855  ‐0.0294, 0.3773 
  Spectinomycin  45  48.89  44  52.27  0.7496  0.0338  ‐0.1673, 0.2312 
  Tilmicosin  45  82.22  40  80  0.7936  0.0222  ‐0.1433, 0.1924 
  Tulathromycin  45  62.22  38  73.68  0.2668  0.1146  ‐0.0871, 0.2995 




Ceftiofur  148  97.97  127  100  0.1544  0.0203  ‐0.012, 0.0579 
  Danofloxacin  44  100  64  100  N/A  0  ‐0.0803, 0.0566 
  Enrofloxacin  147  31.97  127  51.18  0.0013  0.1921  0.0752, 0.3024 
  Florfenicol  147  52.38  133  69.17  0.0041  0.1679  0.0533, 0.2759 
  Spectinomycin  147  22.45  133  51.13  <0.001  0.2868  0.1748, 0.3895 
  Tilmicosin  147  30.61  133  41.35  0.061  0.1074  ‐0.0049, 0.2167 
  Tulathromycin 
 




Ampicillin  70  98.57  91  93.41  0.11230  0.0516  ‐0.02, 0.1232 
  Ceftiofur  68  100  90  98.89  0.5696  0.0111  ‐0.0431, 0.0603 
  Chlortetracycline  59  89.83  70  90.00  0.7898  0.0017  ‐0.1054, 0.1165 
  Danofloxacin  58  100  81  100  N/A  0  ‐0.0621, 0.0453 
  Enrofloxacin  70  88.57  90  92.22  0.4319  0.0365  ‐0.056, 0.1398 
  Florfenicol  70  92.86  92  94.57  0.6545  0.1076  ‐0.0609, 0.1076 
  Oxytetracycline  59  55.93  70  55.71  0.9802  0.0022  ‐0.1656, 0.1687 
  Penicillin  68  85.29  90  73.33  0.0701  0.1196  ‐0.011, 0.2386 
  Spectinomycin  70  54.29  92  65.22  0.1586  0.1093  ‐0.0415, 0.2557 
  Sulfadimethoxine  59  11.86  70  8.20  0.1764  0.0615  ‐0.1186, 0.0571 
  Tilmicosin  59  72.88  70  64.29  0.2962  0.086  ‐0.0753, 0.2378 
  Tulathromycin 
 
67  88.06  90  83.33  0.4075  0.0473  ‐0.07, 0.1544 
Salmonella*  Enrofloxacin  37  100  21  100  N/A  0  ‐0.0941, 0.1546 
 Gentamicin  38  97.37  25  100  0.6032  0.0263  ‐0.1086, 0.1349 















There was no significant change in E. coli’s susceptibility to chlortetracycline (p-value = 
0.5734, CI -0.0719, 0.1309), and enrofloxacin (p-value = 0.0660, CI -0.0057, 0.1485).  There 
was a significant change in E. coli’s susceptibility to ampicillin (p-value = 0.0243, CI 0.0138, 
0.1928), gentamicin (p-value = 0.002, CI 0.0387, 0.1649), neomycin (p-value = 0.0003, CI 
0.0731, 0.2334, and oxytetracycline (p-value = 0.0444, CI 0.0027, 0.2032).  In reviewing the 
susceptibility graphs, none of those showed a decrease in susceptibility.  See Appendix C for 
E. coli’s susceptibility trend graphs, 2012-2017.   
 
Enterococcus 
There was no significant change in Enterococcus’s susceptibility to gentamicin (p-value = 
0.6868, CI -0.3727, 0.3643).  Enterococcus’s susceptibility to ampicillin and penicillin was 
100% in both 2012 and 2017.    There was a significant decrease in Enterococcus’s 
susceptibility to trimethoprim/sulphamethoxazole (p-value = <0.001, CI 0.5243, 1); however, 
there were generally few isolates on Enterococcus per year (<30 in 2012, 2013, 2014, 2016, 
2017) challenged with this antibiotic.  There were only five isolates of Enterococcus in 2017 
with results to trimethoprim/sulphamethoxazole.  See Appendix D for Enterococcus’s 
susceptibility trend graphs, 2012-2017. 
 
Histophilus somni 
There was no significant change in Histophilus somni’s susceptibility to florfenicol (p-value = 
0.0987, CI -0.0034, 0.2718), oxytetracycline (p-value = 0.0923, CI -0.0294, 0.3773, 







0.1924), and tulathromycin (p-value = 0.2668, CI -0.0871, 0.2995).  Histophilus somni’s 
susceptibility to ampicillin and ceftiofur was 100% in both 2012 and 2017.  There was a 
significant increase in Histophilus somni’s susceptibility to enrofloxacin (p-value = 0.0028, CI 




There was no significant change in Mannheimia haemolytica’s susceptibility to ceftiofur (p-
value = 0.1544, CI -0.012, 0.0579) and tilmicosin (p-value = 0.061, CI -0.0049, 0.2167).  
Mannheimia haemolytica’s susceptibility to danofloxacin was 100% in both 2012 and 2017.    
There was a significant increase in Mannheimia haemolytica’s susceptibility to enrofloxacin (p-
value = 0.0013, CI 0.0752, 0.3024), florfenicol (p-value = 0.0041, CI 0.0533, 0.2759), 
spectinomycin (p-value = <0.001, CI 0.1748, 0.3895), and tulathromycin (p-value = 0.0023, CI 




There was no significant change in Pasteurella multocida’s susceptibility to ampicillin (p-value 
= 0.1123, CI -0.02, 0.1232), ceftiofur (p-value = 0.5696, CI -0.0431, 0.0603), chlortetracycline 
(p-value = 0.7898, CI -0.1054, 0.1165), danofloxacin (100% susceptible in 2012 and 2017), 
enrofloxacin (p-value = 0.4319, CI -0.056, 0.1398), florfenicol (p-value = 0.6545, CI -0.0609, 
0.1076), oxytetracycline (p-value = 0.9802, CI -0.1656, 0.1687), penicillin (p-value = 0.0701, CI 







value = 0.1764, CI -0.1186, 0.0571), tilmicosin (p-value = 0.2962, CI -0.0753, 0.2378), and 
tulathromycin (p-value = 0.4075, CI -0.07, 0.1544).  See Appendix G for Pasteurella 
multocida’s susceptibility trend graphs, 2012-2017. 
 
Salmonella 
There was no significant change in Salmonella’s susceptibility to gentamicin (p-value = 0.6032, 
CI -0.1086, 0.1349) and sulfadimethoxine (p-value = 0.4623, CI = -0.1187, 0.2916).  
Salmonella’s susceptibility to enrofloxacin was 100% in both 2012 and 2017.  See Appendix H 
for Salmonella’s susceptibility trend graphs, 2012-2017. 
  
Antibiograms 
 The first antibiogram (Figure 3) developed displays the results for Kentucky with both 
laboratories results consolidated.  Susceptibility is reported as good (>90%), fair (70-89%), and 
poor (<70%). 
Ampicillin displays good activity against Enterococcus, Histophilus somni, and 
Pasteurella multocida, while it displays fair activity against E. coli.  Ceftiofur displays good 
activity against Histophilus somni, Mannheimia haemolytica, and Pasteurella multocida.  
Chlortetracycline displays good activity Pasteurella multocida, but displays poor activity against 
chlortetracycline.  Danofloxacin displays good activity against Mannheimia haemolytica, and 
Pasteurella multocida.  Enrofloxacin displays good activity against Pasteurella multocida and 
Salmonella, fair activity against E. coli and Histophilus somni, and poor activity against 
Mannheimia haemolytica.  Florfenicol displays good activity against Histophilus somni and 







Gentamicin displays good activity against E. Coli and Salmonella, while it displays poor activity 
against Enterococcus.  Neomycin displays fair activity against E. coli.  Oxytetracycline 
displayed poor activity against E. coli, Histophilus somni, and Pasteurella multocida.  Penicillin 
displayed good activity against Enterococcus and fair activity against Pasteurella multocida.  
Spectinomycin displayed poor activity against Histophilus somni, Mannheimia haemolytica, 
and Pasteurella multocida.  Sulfadimethoxine displayed poor activity against Pasteurella 
multocida and Salmonella.  Tilmicosin displayed fair activity against Histophilus somni and 
poor activity against Mannheimia haemolytica.  Trimethoprim/Sulphamethoxazole displayed 
poor activity against enterococcus.  Tulathromycin displayed fair activity against Histophilus 




Amp  Ceft  Chlor  Dano  Enro  Flor  Gent  Neo  Oxytet  Pen  Spec  Sulfa  Tilm 
TMP/ 
SMZ  Tula 
                                               
E. Coli  71  N/A  44  N/A  88  N/A  93  88  45  N/A  N/A  N/A  N/A  N/A  N/A 
                    
Enterococcus  100  N/A  N/A  N/A  N/A  N/A  29**  N/A  N/A  95**  N/A  N/A  N/A  30**  N/A 
                    
Histophilus somni  100  100  N/A  N/A  84  95  N/A  N/A  48  N/A  52  N/A  80  N/A  74 
                    
Mannheimia  N/A  100  N/A  100  51  69  N/A  N/A  N/A  N/A  51  N/A  41  N/A  55 
haemolytica 
                 
Pasteurella multocida  93  99  90  100  92  95  N/A  N/A  56  73  65  6  64  N/A  83 
                    
Salmonella  N/A  N/A  N/A  N/A  100**  N/A  93**  N/A  N/A  N/A  N/A  13**  N/A  N/A  N/A 















 This second antibiogram displays Mannheimia haemolytica’s susceptibility by ADD 
using data from both the UKVDL and the MSU-BVC.  Ceftiofur and danofloxacin displayed 
good activity against Mannheimia haemolytica in all ADDs.  Enrofloxacin displayed good 
activity in FIVCO, though only one sample had been submitted, and displayed poor activity 
against Mannheimia haemolytica in all other ADDs.  Florfenicol displayed good activity in 
FIVCO, though only one sample had been submitted, fair activity in Gateway, Green River, 
KIPDA, and Pennyrile, and it displayed poor activity against Mannheimia haemolytica in all 
other ADDs.  Tilmicosin display poor activity against Mannheimia haemolytica in all ADDs, and 
again only one sample was submitted from FIVCO. Tulathromycin displayed good activity in 
FIVCO, though only one sample had been submitted, and displayed poor activity against 
Mannheimia haemolytica in all other ADDs.  Table 3 displays the number of isolates by ADD 
for each antibiotic.  ADDs with fewer than 5 isolates for a given antibiotic from 2012 through 
2017 will not be included in the maps; however, they will still be included in the cumulative 
antibiogram table (Figure 5). 
 
ADD  Ceftiofur  Danofloxacin  Enrofloxacin  Florfenicol  Tilmicosin  Tulathromycin 
Barren River  41  28  41  30  30  41 
Big Sandy  0  0  0  0  0  0 
Bluegrass  58  53  58  58  58  56 
Buffalo Trace  36  23  37  36  36  36 
Cumberland Valley  18  11  18  18  18  18 
FIVCO  1  1  1  1  1  1 
Gateway  32  19  32  32  32  37 
Green River  12  6  12  13  13  12 
KIPDA  36  21  36  36  36  36 
Kentucky River  28  4  28  28  28  31 
Lake Cumberland  35  24  35  35  35  35 
Lincoln Trace  37  16  37  38  38  37 
Northern Kentucky  19  5  19  19  19  19 
Pennyrile  35  28  35  37  37  35 
Purchase  17  6  17  17  17  17 
Kentucky (State, 2017)  405  245  406  398  398  411 











ADD  Ceft     Dano     Enro     Flor     Tilm     Tula 
  
     
        
Barren River  98    100    44    63    40    46 
                
Big Sandy2  N/A    N/A    N/A    N/A    N/A    N/A 
                
Bluegrass  100    100    50    69    45    57 
                
Buffalo Trace  100    100    51    56    39    64 
                
Cumberland Valley  100    100    56    61    50    67 
                
FIVCO3  100    100    100    100    0    100 
                
Gateway  100    100    53    75    41    57 
                
Green River  100    100    50    77    38    50 
     
KIPDA  100  100  56  72  47  56 
                
Kentucky River  100    100    14    46    11    23 
                
Lake Cumberland  100    100    34    69    26    37 
                
Lincoln Trail  100    100    43    53    34    49 
                
Northern Kentucky  95    100    32    53    21    32 
                
Pennyrile  97    100    57    70    43    57 
                
Purchase  100    100    35    59    35    41 
                














 Antibiograms can also be displayed as a map and can provide great information over 
time when reviewing trend analysis and potentially when looking for spatial correlations.  In 
ArcMap, the susceptibilities were associated with the appreciate Area Development District.  


































This study showed that the majority of isolate/antibiotic pairings had no significant 
change in susceptibility from 2012 to 2017 in Kentucky.   30 of the 40 pairings showed no 
change, with 7 of those pairing displaying 100% susceptibility in 2012 and 2017.  Of the 10 
pairings that did display a significant change in susceptibility, only 1 showed a decrease in 
susceptibility while the other 9 showed an increase in susceptibility.  This was surprising given 
the time (6 years) this study spans.  The decreased susceptibility of Enterococcus against 
trimethoprim/sulphamethoxazole was clinically significant as it dropped from good 
susceptibility (100%) in 2012 to poor (0%) in 2016 and 2017.  The increase in Histophilus 
somni’s susceptibility to enrofloxacin is also clinically significant as it rose from 53% 
susceptibility (poor) to 84% (fair).  There was variation in the graphs from year to year, but 
these annual differences were not measured in this study. 
Ceftiofur, released in 1988, continues to have good activity against the most important 
BRD bacterial pathogens.  Only gentamicin had good activity against E. coli.  Oxytetracycline 
exhibited poor activity against E. coli, Histophilus somni, and Pasteurella multocida.  This is 
concerning, and probably not surprising, as oxytetracycline’s widespread availability as an 
over-the-counter product in farm supply stores in Kentucky and online.  Pasteurella multocida 
remains susceptible to ampicillin, ceftiofur, chlortetracycline, danofloxacin, and florfenicol.  
Tilmicosin displayed poor activity to Pasteurella, similar to Portis et al.[19]  According to the 
results in this study, spectinomycin is a poor choice in Kentucky for BRD metaphylaxsis and 
treatment as it had poor activity against the three key BRD bacteria.  Spectinomycin is also 
available over-the-counter, but the spectinomycin found in a Kentucky farm supply store was 







also available over-the-counter in several forms and can be purchased online through a variety 
of stores with a veterinary prescription.  Ampicillin, ceftiofur, and florfenicol appear to be good 
choices against Histophilus somni.  Mannheimia haemolytica was found to be 100% 
susceptible to danofloxacin compared to the 88% susceptibility found in study conducted by 
Portis et al.[19] 
23 of the 40 isolate/antibiotic pairings showed an increase in susceptibility, though most 
(14) of these were not statistically significant.  It will be important to monitor these changes in 
susceptibility over time to possibly interpret the impact of the Veterinary Feed Directive 
eliminating antibiotics considered medically important in human healthcare from being used as 
sub-therapeutic growth promoters in animal feeds.  At the time of this paper, the VFD has only 
been in effect for a little over a year, so it is too early to determine the full potential impact on 
bacterial susceptibility. 
Single, isolated interventions have limited impact and this is why coordinated action is 
required to minimize the emergence and spread of antimicrobial resistance.[1]  Antimicrobial 
agents used for the treatment of BRD are selected by the veterinarian on the basis of 
perceived efficacy, cost, convenience, availability, toxicity, and residue profile[33].  However, 
veterinarians should base their treatments on the most recent available data and antibiograms 
can assist with good antimicrobial stewardship.  The Veterinary Feed Directive is another step 
in the right direction in pursuing good antimicrobial stewardship.  However, these efforts are 
undermined with the availability of important antibiotics in local farm supply stores and online.  
Exposure of bacteria to antimicrobial drugs has the potential to exert pressure for selection of 
resistant organisms and, in order to retain efficacy, veterinarians and producers are advised to 







The isolates from this study were presumed to originate from unhealthy animals, which 
is dissimilar from NARMS surveillance of cattle caeca after slaughter, from animals that are 
presumed to be healthy in order to enter the human food-chain.  A comparison of these 
numbers would not be valuable.  NARMS does not have a surveillance program in Kentucky.  
With the large numbers of beef and poultry animals, it may be a worthy venture to create a 
partnership between the USDA and Kentucky’s health departments and/or universities.  
NARMS monitors Campylobacter, E. coli, and Enterococcus, and Salmonella resistance as 
they are zoonotic agents and have potential to share resistance through plasmid transfer.[12]  
Given the increasing trend of resistance in these bacteria, it is important to monitor their 
resistance to key antibiotics.[34, 35]  It has also been noted that Pasteurella multocida has 
zoonotic potential, while human cases of Mannheimia haemolytica are rare.[36]   
 
Summary 
It will be important to continue to monitor use of antibiotics that are considered medically 
important in human medicine.  The Veterinary Feed Directive is a step in the right direction to 
promote good antibiotic stewardship.  Antibiotics used in metaphylaxsis should be reviewed for 
susceptibility to ensure the proper antibiotics are used in a given population.  Antibiograms, 
whether a chart or a map, can be beneficial for veterinarians in their antibiotic selection.  
Though some of the antibiotics in this study are specifically labelled for use in animals, 
transference of resistance to antibiotics in the same class from one bacteria species to another 
can occur, potentially having an impact in the number and type of antimicrobial resistance 









 Sampling is subject to a selection bias as all samples are presumed to be submitted 
from sick animals.  This makes it difficult to determine prevalence or resistant bacteria in a 
population and compare to studies that have been conducted in feedlots where sampling 
includes sick and healthy animals.  Not all infections are cultured, meaning varied frequency of 
bacterial cultures being submitted and may lead to biased estimates, but the magnitude of bias 
cannot be assessed from the data reviewed in this study.[37]  This sort of selection may be 
appropriate in antibiogram development as the concern is treating ill patients within the sample 
population; however, developing antibiograms for subpopulations, such as counties, could 
provide more accurate antibiograms for these smaller populations. 
Low numbers of samples in certain areas made it difficult to evaluate resistance at the 
county level.  County-level information would be more valuable to reduce the likelihood of 
ecological fallacy.  County-level antibiograms would provide better antibiograms to help guide 
the food supply veterinarian in developing metaphylaxsis and treatment protocols in their 
service areas.  Multi-drug resistance was not evaluated in this study.  These isolates were not 
confirmed to be from cattle diagnosed with BRD.  This study did not look at the impact of cost 
of treatment per antibiotic, but hat could be a contributing factor as economics may drive the 
overuse of cheaper antibiotics, causing selective pressure in their target organisms, and 
leading to increased antimicrobial resistance.  The changes in susceptibility could be due to 
underlying natural fluctuations of resistance and, given that this study only covers six years, 
these changes should be monitored over a longer period of time to best determine long-term 









 The author of this study is in the United States Army and on active duty status.  None of 
the opinions in this paper reflect those of the United States Army, Department of Defense, or 
































































































































Appendix A: Medically Important Antibiotics in Human Health (Source: USDA1)
 
1. The World Health Organization lists Trimethoprim/Sulphamethoxazole as a highly 









Appendix B: Categorized List of Antimicrobials Reviewed in this Study1 
Importance Antimicrobial Antibiotic Class 
   
Critically Important Ceftiofur 3rd Generation Cephalosporin 
 Danofloxacin Fluoroquinolone 
 Enrofloxacin Fluoroquinolone 
 Tilmicosin Macrolide 
 Tulathromycin Macrolide 
   
   
Highly Important Ampicillin2 Penicillin 
 Chlortetracycline2 Tetracycline 
 Florfenicol Phenicol 
 Gentamicin2 Aminoglycoside 
 Neomycin Aminoglycoside 
 Oxytetracycline Tetracycline 
 Penicillin2 Penicillin 
 Sulfadimethoxine Sulfonamides 
 Trimethoprim/Sulphamethoxazole2 Sulfonamides 
   
   
Important Spectinomycin2 Aminocyclitols 
   
   
 
1. List created as compared to the World Health Organization’s list of medically important 
antimicrobials. http://apps.who.int/iris/bitstream/handle/10665/255027/9789241512220-
eng.pdf;jsessionid=7AE6AEBA0C754E395659FE3A641AB2D5?sequence=1 
2. These antibiotics are specifically listed by the WHO as they are used in human 
medicine.  The remaining antibiotics are labeled for use in animal medicine and fit into 










































Appendix D: Enterococcus susceptibility trends to select antibiotics, 2012-2017 
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Histophilus somni Susceptibility to Enrofloxacin












Histophilus somni Susceptibility to Florfenicol
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Appendix H: Salmonella’s susceptibility trends to select antibiotics, 2012-2017 
 
 
    
     
 
